Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Glivec
Glivec 100 mg film-coated tablets Glivec 400 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 10
HOS-110221 · Präparat HOS-093339
Substances that are inducers of CYP3A4 activity (e.g. dexamethasone, phenytoin, carbamazepine,
rifampicin, phenobarbital, fosphenytoin, primidone or Hypericum perforatum, also known as St.
John’s Wort) may significantly reduce exposure to Glivec, potentially increasing the risk of
therapeutic failure. Pretreatment with multiple doses of rifampicin 600 mg followed by a single
400 mg dose of Glivec resulted in decrease in Cmax and AUC(0-∞) by at least 54% and 74%, of the
respective values without rifampicin treatment. Similar results were observed in patients with
malignant gliomas treated with Glivec while taking enzyme-inducing anti-epileptic drugs (EIAEDs)
such as carbamazepine, oxcarbazepine and phenytoin. The plasma AUC for imatinib decreased by
73% compared to patients not on EIAEDs. Concomitant use of rifampicin or other strong CYP3A4
inducers and imatinib should be avoided.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): fosphenytoin (HOS-110222) phenobarbital (HOS-085617) carbamazepine (HOS-085618) dexamethasone (HOS-084535) oxcarbazepine (HOS-110224) phenytoin (HOS-084531) primidone (HOS-090551)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-12T09:28:00Z · SHA-256 838bc114dc50fcc5141e52ce7cbac64366b6fd4a03bb5a5e7a5ec09cf8be0b00 · Passage bb17575a294e1c6ea67d8805646bff3038e1cfd96e17f699d0cea24ccaeb8458 · Zeichen 875–1767 im Abschnitt
Wechselwirkungen · Exforge
Exforge 5 mg/80 mg film-coated tablets Exforge 5 mg/160 mg film-coated tablets Exforge 10 mg/160 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 6
HOS-117030 · Präparat HOS-094529
CYP3A4 inducers (anticonvulsant agents [e.g. carbamazepine, phenobarbital, phenytoin,
fosphenytoin, primidone], rifampicin, Hypericum perforatum)
Upon co-administration of known inducers of the CYP3A4, the plasma concentration of amlodipine
may vary. Therefore, blood pressure should be monitored and dose regulation considered both during
and after concomitant medication particularly with strong CYP3A4 inducers (e.g. rifampicin,
hypericum perforatum).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): fosphenytoin (HOS-110222) phenobarbital (HOS-085617) carbamazepine (HOS-085618) amlodipine (HOS-086287) phenytoin (HOS-084531) primidone (HOS-090551)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-19T14:05:00Z · SHA-256 c0f20d1cd1f31fe3cb10c75d388584e384179f190aefe9b5aa18ab44fe066abd · Passage cae7ac2dde94934ade6d5533150213e54925ba72f27ff86f857d96528d595cd8 · Zeichen 1272–1726 im Abschnitt
Wechselwirkungen · Copalia
Copalia 5 mg/80 mg film-coated tablets Copalia 5 mg/160 mg film-coated tablets Copalia 10 mg/160 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 6
HOS-117728 · Präparat HOS-094681
CYP3A4 inducers (anticonvulsant agents [e.g. carbamazepine, phenobarbital, phenytoin,
fosphenytoin, primidone], rifampicin, Hypericum perforatum)
Upon co-administration of known inducers of the CYP3A4, the plasma concentration of amlodipine
may vary. Therefore, blood pressure should be monitored and dose regulation considered both during
and after concomitant medication particularly with strong CYP3A4 inducers (e.g. rifampicin,
hypericum perforatum).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): fosphenytoin (HOS-110222) phenobarbital (HOS-085617) carbamazepine (HOS-085618) amlodipine (HOS-086287) phenytoin (HOS-084531) primidone (HOS-090551)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-19T12:43:00Z · SHA-256 ff02e70e0f3fe7a3fb94d2963c4154f946936506ae5d98b0833bbd070c73ea06 · Passage cae7ac2dde94934ade6d5533150213e54925ba72f27ff86f857d96528d595cd8 · Zeichen 1272–1726 im Abschnitt
Wechselwirkungen · Dafiro
Dafiro 5 mg/80 mg film-coated tablets Dafiro 5 mg/160 mg film-coated tablets Dafiro 10 mg/160 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 6
HOS-117767 · Präparat HOS-094689
CYP3A4 inducers (anticonvulsant agents [e.g. carbamazepine, phenobarbital, phenytoin,
fosphenytoin, primidone], rifampicin, Hypericum perforatum)
Upon co-administration of known inducers of the CYP3A4, the plasma concentration of amlodipine
may vary. Therefore, blood pressure should be monitored and dose regulation considered both during
and after concomitant medication particularly with strong CYP3A4 inducers (e.g. rifampicin,
hypericum perforatum).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): fosphenytoin (HOS-110222) phenobarbital (HOS-085617) carbamazepine (HOS-085618) phenytoin (HOS-084531) primidone (HOS-090551)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-19T13:43:00Z · SHA-256 79620834a2f80d9411f50ae6b7ff4251fbeff4573f3af37e14d730cfb3d0f1a2 · Passage cae7ac2dde94934ade6d5533150213e54925ba72f27ff86f857d96528d595cd8 · Zeichen 1271–1725 im Abschnitt
Wechselwirkungen · ellaOne
ellaOne 30 mg tablet · Abschnitt 4.5 · PDF-Seite 4
HOS-121383 · Präparat HOS-095343
Ulipristal acetate is metabolised by CYP3A4 in vitro.
- CYP3A4 inducers
In vivo results show that the administration of ulipristal acetate with a strong CYP3A4 inducer
such as rifampicin markedly decreases Cmax and AUC of ulipristal acetate by 90% or more and
decreases ulipristal acetate half-life by 2.2-fold corresponding to an approximately 10-fold
decrease of ulipristal acetate exposure. Concomitant use of ellaOne with CYP3A4 inducers (e.g.
barbiturates (including primidone and phenobarbital), phenytoin, fosphenytoin, carbamazepine,
oxcarbazepine, herbal medicines containing Hypericum perforatum (St. John’s wort),
rifampicin, rifabutin, griseofulvin, efavirenz and nevirapine) therefore reduces plasma
concentrations of ulipristal acetate and may result in a decreased efficacy of ellaOne. For
women who have used enzyme-inducing drugs in the past 4 weeks, ellaOne is not recommended
(see section 4.4) and non-hormonal emergency contraception (i.e. a copper intrauterine device
(Cu-IUD)) should be considered.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): fosphenytoin (HOS-110222) phenobarbital (HOS-085617) carbamazepine (HOS-085618) rifabutin (HOS-086262) griseofulvin (HOS-091156) ulipristal acetate (HOS-121379) copper (HOS-112734) efavirenz (HOS-087947) nevirapine (HOS-088064) oxcarbazepine (HOS-110224) phenytoin (HOS-084531) primidone (HOS-090551)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-09-29T13:44:00Z · SHA-256 3bcc90490ab5bf0dd081a2d800bb02d498a50e916a38764a4f0fc343e4f5e8b6 · Passage 87464f734672865ea9df447f4532cd92447404847005d1bb51fb5ed63267d21a · Zeichen 69–1159 im Abschnitt
Wechselwirkungen · ellaOne
ellaOne 30 mg film-coated tablet · Abschnitt 4.5 · PDF-Seite 15
HOS-121411 · Präparat HOS-095343
Ulipristal acetate is metabolised by CYP3A4 in vitro.
- CYP3A4 inducers
In vivo results show that the administration of ulipristal acetate with a strong CYP3A4 inducer
such as rifampicin markedly decreases Cmax and AUC of ulipristal acetate by 90% or more and
decreases ulipristal acetate half-life by 2.2-fold corresponding to an approximately 10-fold
decrease of ulipristal acetate exposure. Concomitant use of ellaOne with CYP3A4 inducers (e.g.
barbiturates (including primidone and phenobarbital), phenytoin, fosphenytoin, carbamazepine,
oxcarbazepine, herbal medicines containing Hypericum perforatum (St. John’s wort),
rifampicin, rifabutin, griseofulvin, efavirenz and nevirapine) therefore reduces plasma
concentrations of ulipristal acetate and may result in a decreased efficacy of ellaOne. For
women who have used enzyme-inducing drugs in the past 4 weeks, ellaOne is not recommended
(see section 4.4) and non-hormonal emergency contraception (i.e. a copper intrauterine device
(Cu-IUD)) should be considered.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): fosphenytoin (HOS-110222) phenobarbital (HOS-085617) carbamazepine (HOS-085618) rifabutin (HOS-086262) griseofulvin (HOS-091156) ulipristal acetate (HOS-121379) copper (HOS-112734) efavirenz (HOS-087947) nevirapine (HOS-088064) oxcarbazepine (HOS-110224) phenytoin (HOS-084531) primidone (HOS-090551)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-09-29T13:44:00Z · SHA-256 3bcc90490ab5bf0dd081a2d800bb02d498a50e916a38764a4f0fc343e4f5e8b6 · Passage 87464f734672865ea9df447f4532cd92447404847005d1bb51fb5ed63267d21a · Zeichen 69–1159 im Abschnitt
Wechselwirkungen · Exforge HCT
Exforge HCT 5 mg/160 mg/12.5 mg film-coated tablets Exforge HCT 10 mg/160 mg/12.5 mg film-coated tablets Exforge HCT 5 mg/160 mg/25 mg film-coated tablets Exforge HCT 10 mg/160 mg/25 mg film-coated tablets Exforge HCT 10 mg/320 mg/25 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 9
HOS-121625 · Präparat HOS-095405
Exforge Known interactions Effect of the interaction with other medicinal products
HCT with the following
individual agents
component
Amlodipine CYP3A4 inhibitors Concomitant use of amlodipine with strong or moderate
(i.e. ketoconazole, CYP3A4 inhibitors (protease inhibitors, azole antifungals,
itraconazole, ritonavir) macrolides like erythromycin or clarithromycin, verapamil
or diltiazem) may give rise to significant increase in
amlodipine exposure. The clinical translation of these
pharmacokinetic variations may be more pronounced in
the elderly. Clinical monitoring and dose adjustment may
thus be required.
CYP3A4 inducers Upon co-administration of known inducers of the
(anticonvulsant agents CYP3A4, the plasma concentration of amlodipine may
[e.g. carbamazepine, vary. Therefore, blood pressure should be monitored and
phenobarbital, dose regulation considered both during and after
phenytoin, concomitant medication particularly with strong CYP3A4
fosphenytoin, inducers (e.g. rifampicin, hypericum perforatum).
primidone], rifampicin,
Hypericum perforatum
[St. John’s wort])
Simvastatin Co-administration of multiple doses of 10 mg amlodipine
with 80 mg simvastatin resulted in a 77% increase in
exposure to simvastatin compared to simvastatin alone. It
is recommended to limit the dose of simvastatin to 20 mg
daily in patients on amlodipine.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): fosphenytoin (HOS-110222) diltiazem (HOS-086288) protease (HOS-085623) phenobarbital (HOS-085617) ketoconazole (HOS-084513) carbamazepine (HOS-085618) simvastatin (HOS-086158) itraconazole (HOS-084516) clarithromycin (HOS-084517) erythromycin (HOS-084514) ritonavir (HOS-084521) phenytoin (HOS-084531) primidone (HOS-090551) verapamil (HOS-090602)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-02-06T15:33:00Z · SHA-256 2096581c7b0afb2c48317340c55eeef559ee192a2bef927e9adeba55285d5694 · Passage a069f5c5d746fbdfd20000c5b575b645e137cad662c876de1aa3e9cc2e035747 · Zeichen 2337–4382 im Abschnitt
Wechselwirkungen · Copalia HCT
Copalia HCT 5 mg/160 mg/12.5 mg film-coated tablets Copalia HCT 10 mg/160 mg/12.5 mg film-coated tablets Copalia HCT 5 mg/160 mg/25 mg film-coated tablets Copalia HCT 10 mg/160 mg/25 mg film-coated tablets Copalia HCT 10 mg/320 mg/25 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 9
HOS-122662 · Präparat HOS-095555
Copalia Known interactions Effect of the interaction with other medicinal products
HCT with the following
individual agents
component
Amlodipine CYP3A4 inhibitors Concomitant use of amlodipine with strong or moderate
(i.e. ketoconazole, CYP3A4 inhibitors (protease inhibitors, azole antifungals,
itraconazole, ritonavir) macrolides like erythromycin or clarithromycin, verapamil
or diltiazem) may give rise to significant increase in
amlodipine exposure. The clinical translation of these
pharmacokinetic variations may be more pronounced in
the elderly. Clinical monitoring and dose adjustment may
thus be required.
CYP3A4 inducers Upon co-administration of known inducers of the
(anticonvulsant agents CYP3A4, the plasma concentration of amlodipine may
[e.g. carbamazepine, vary. Therefore, blood pressure should be monitored and
phenobarbital, dose regulation considered both during and after
phenytoin, concomitant medication particularly with strong CYP3A4
fosphenytoin, inducers (e.g. rifampicin, hypericum perforatum).
primidone], rifampicin,
Hypericum perforatum
[St. John’s wort])
Simvastatin Co-administration of multiple doses of 10 mg amlodipine
with 80 mg simvastatin resulted in a 77% increase in
exposure to simvastatin compared to simvastatin alone. It
is recommended to limit the dose of simvastatin to 20 mg
daily in patients on amlodipine.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): fosphenytoin (HOS-110222) diltiazem (HOS-086288) protease (HOS-085623) phenobarbital (HOS-085617) ketoconazole (HOS-084513) carbamazepine (HOS-085618) simvastatin (HOS-086158) itraconazole (HOS-084516) clarithromycin (HOS-084517) erythromycin (HOS-084514) ritonavir (HOS-084521) phenytoin (HOS-084531) primidone (HOS-090551) verapamil (HOS-090602)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-02-06T11:21:00Z · SHA-256 230f24622c23683c6a46653c5bf6b1c68bc72aa3359d9f8eed8a17a080938906 · Passage bd115acc15a57ba40299d7071bcb2b97baf3ba922704effe6ae74a09aaaa91f6 · Zeichen 2337–4382 im Abschnitt
Wechselwirkungen · Dafiro HCT
Dafiro HCT 5 mg/160 mg/12.5 mg film-coated tablets Dafiro HCT 10 mg/160 mg/12.5 mg film-coated tablets Dafiro HCT 5 mg/160 mg/25 mg film-coated tablets Dafiro HCT 10 mg/160 mg/25 mg film-coated tablets Dafiro HCT 10 mg/320 mg/25 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 9
HOS-122719 · Präparat HOS-095563
Dafiro HCT Known interactions Effect of the interaction with other medicinal products
individual with the following
component agents
Amlodipine CYP3A4 inhibitors Concomitant use of amlodipine with strong or moderate
(i.e. ketoconazole, CYP3A4 inhibitors (protease inhibitors, azole antifungals,
itraconazole, ritonavir) macrolides like erythromycin or clarithromycin, verapamil
or diltiazem) may give rise to significant increase in
amlodipine exposure. The clinical translation of these
pharmacokinetic variations may be more pronounced in
the elderly. Clinical monitoring and dose adjustment may
thus be required.
CYP3A4 inducers Upon co-administration of known inducers of the
(anticonvulsant agents CYP3A4, the plasma concentration of amlodipine may
[e.g. carbamazepine, vary. Therefore, blood pressure should be monitored and
phenobarbital, dose regulation considered both during and after
phenytoin, concomitant medication particularly with strong CYP3A4
fosphenytoin, inducers (e.g. rifampicin, hypericum perforatum).
primidone], rifampicin,
Hypericum perforatum
[St. John’s wort])
Simvastatin Co-administration of multiple doses of 10 mg amlodipine
with 80 mg simvastatin resulted in a 77% increase in
exposure to simvastatin compared to simvastatin alone. It
is recommended to limit the dose of simvastatin to 20 mg
daily in patients on amlodipine.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): fosphenytoin (HOS-110222) diltiazem (HOS-086288) protease (HOS-085623) phenobarbital (HOS-085617) ketoconazole (HOS-084513) carbamazepine (HOS-085618) simvastatin (HOS-086158) itraconazole (HOS-084516) clarithromycin (HOS-084517) erythromycin (HOS-084514) ritonavir (HOS-084521) phenytoin (HOS-084531) primidone (HOS-090551) verapamil (HOS-090602)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-02-06T17:50:00Z · SHA-256 ac895b922284b71e7c5c23e23c9993c138af1676fdc3c53bcfaa54fe9f7593a7 · Passage 4cb021b0257c2e72f8b5b84e3a74101793292dce375980b5697de883cec1054d · Zeichen 2324–4358 im Abschnitt
Wechselwirkungen · Amlodipine / Valsartan Mylan
Amlodipine/Valsartan Mylan 5 mg/80 mg film-coated tablets Amlodipine/Valsartan Mylan 5 mg/160 mg film-coated tablets Amlodipine/Valsartan Mylan 10 mg/160 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 6
HOS-133843 · Präparat HOS-097512
CYP3A4 inducers (anticonvulsant agents [e.g. carbamazepine, phenobarbital, phenytoin,
fosphenytoin, primidone], rifampicin, Hypericum perforatum)
Upon co-administration of known inducers of the CYP3A4, the plasma concentration of amlodipine
may vary. Therefore, blood pressure should be monitored and dose regulation considered both during
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): fosphenytoin (HOS-110222) phenobarbital (HOS-085617) carbamazepine (HOS-085618) phenytoin (HOS-084531) primidone (HOS-090551)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-12T11:47:00Z · SHA-256 7f4ea9a016c1c5f16eb5128d72832436673fdb577b23bdb2d2f9ab3ecc9d2df3 · Passage 260c882597407e39808e42c2e939f5eeb95cdca4feabae9985aac5591e9dbf77 · Zeichen 1225–1564 im Abschnitt
Wechselwirkungen · Voranigo
Voranigo 10 mg film-coated tablets Voranigo 40 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7
HOS-152390 · Präparat HOS-100749
Co-administration of vorasidenib with CYP2B6, CYP2C8, CYP2C9, CYP2C19, or CYP3A4 substrates
with narrow therapeutic index (including, but not limited to, amitriptyline, alfentanil, carbamazepine,
ciclosporin, dosulepin, everolimus, fentanyl, fosphenytoin, ifosfamide, imipramine, phenobarbital,
phenytoin, pimozide, quinidine, sirolimus, tacrolimus, tamoxifen, trimipramine, valproic acid, and
warfarin) may decrease the plasma concentrations of these medicinal products. Concomitant use of
substrates of these enzymes with narrow therapeutic index should be avoided in patients taking
vorasidenib.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): fosphenytoin (HOS-110222) alfentanil (HOS-109375) amitriptyline (HOS-085911) phenobarbital (HOS-085617) valproic acid (HOS-088515) trimipramine (HOS-152398) carbamazepine (HOS-085618) imipramine (HOS-085907) tamoxifen (HOS-088380) quinidine (HOS-085593) ifosfamide (HOS-091529) tacrolimus (HOS-085202) pimozide (HOS-085600) everolimus (HOS-086310) sirolimus (HOS-085172) fentanyl (HOS-086196) phenytoin (HOS-084531) warfarin (HOS-085950)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-27T16:33:00Z · SHA-256 2232f34043666605447d216a0f9efae95496605e48741a446bf6879643808d62 · Passage 3d550b9ad3b19c779ebfbf7d68a0ec9fc3073bab44b0453f3efc8e4f9e0983a9 · Zeichen 1607–2205 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.